help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

The Oncologist, Vol. 12, No. 7, 774-784, July 2007; doi:10.1634/theoncologist.12-7-774
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robertson, J. F. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robertson, J. F. R.

Breast Cancer

Fulvestrant (Faslodex®)—How to Make a Good Drug Better

John F. R. Robertson

Professorial Unit of Surgery, Nottingham City Hospital, Nottingham, United Kingdom

Key Words. Breast cancer • Dose–response relationship • Drug • Estrogen receptor • Fulvestrant • Pharmacokinetics

Correspondence: Correspondence: John F. R. Robertson, M.D., Professorial Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, United Kingdom. Telephone: 44-0115-8231876; Fax: 44-0115-8231877; e-mail: john.robertson{at}nottingham.ac.uk

Fulvestrant (Faslodex®; AstraZeneca Pharmaceuticals, Wilmington, DE) is an estrogen receptor (ER) antagonist with a novel mode of action; it binds, blocks, and increases degradation of ER. Fulvestrant (at the approved dose [250 mg/month]) is at least as effective as anastrozole (1 mg/day) in the treatment of postmenopausal women with hormone receptor–positive advanced breast cancer (HR+ ABC) progressing or recurring on antiestrogen therapy, and is also an active first-line treatment. Although fulvestrant (250 mg/month) is clearly effective, it takes 3–6 months to achieve steady-state plasma levels. Steady-state concentrations are approximately twofold higher than those achieved with a single dose; reaching this earlier, for example, via a loading-dose (LD) regimen (250 mg/month plus 500 mg on day 0 and 250 mg on day 14 of month 1), may allow responses to be achieved more quickly and limit the possibility of early relapse.

Fulvestrant high-dose (HD) regimens (500 mg/month) offer the possibility of greater antitumor activity, because (a) ER downregulation is a dose-dependent process (an approximately 70% reduction is observed with a single 250 mg dose of fulvestrant) and (b) evidence correlates greater ER downregulation with superior efficacy. A fulvestrant HD regimen offers the potential of achieving near 100% ER downregulation. There is also potential to increase fulvestrant–ER binding by reducing plasma estrogen levels, for example, with concomitant aromatase inhibitor treatment.

Several ongoing trials use LD, HD, and combination regimens; results from these studies are awaited with interest. Meanwhile, fulvestrant (250 mg/month) remains a valuable additional endocrine treatment for postmenopausal women with HR+ ABC recurring or progressing on antiestrogen therapy.

Disclosure of potential conflicts of interest is found at the end of this article.




This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
L. B. Michaud
Treatment-experienced breast cancer
Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S4 - S9.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. F. Macedo, G. J. Sabnis, O. G. Goloubeva, and A. Brodie
Combination of Anastrozole with Fulvestrant in the Intratumoral Aromatase Xenograft Model
Cancer Res., May 1, 2008; 68(9): 3516 - 3522.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
K. I. Pritchard
Adjuvant Endocrine Therapy of the Future: Potential and Possibilities
ASCO Educational Book, January 1, 2008; 2008(1): 18 - 23.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2007 by AlphaMed Press.